BOC Sciences focuses on powering drug delivery through bioconjugation. Relying on our state-of-the-art manufacturing facilities and comprehensive experience in conjugation technologies, BOC Sciences provides conjugation services to combine oligonucleotides with enzyme. We have the capability and confidence to meet your needs for novel conjugates.
Enzyme-oligonucleotide conjugation is a novel area of drug research that combines two molecules, an enzyme and an oligonucleotide, to form a complex with specific biological activity.
The basic principle of the conjugation process between enzymes and oligonucleotides is determined by the method of binding employed. There are generally two techniques used in modern research: covalent and non-covalent binding. Covalent binding involves altering the structure of oligonucleotides to include reactive groups that can form covalent bonds with amino acid residues found in the enzyme. On the other hand, non-covalent binding involves the enzyme adhering to the oligonucleotide through non-covalent forces, including electrostatic interactions, hydrogen bonds, and van der Waals forces.
The biological activity of enzyme-oligonucleotide conjugation is the key to its application prospects. It has been shown that enzyme-oligonucleotide conjugation can specifically recognize and target the corresponding cells or tissues in vivo. This can be achieved by designing oligonucleotide sequences to be complementary to the target molecule in the target cell or tissue. In addition, enzyme-oligonucleotide conjugation can regulate cellular signaling pathways, inhibit the proliferation of viruses and cancer cells, etc.
Enzyme-oligonucleotide conjugation offers tremendous potential for advancing the field of gene therapy, by enabling precise targeting of genes to specific cells and regulation of gene expression. By fusing gene and oligonucleotide sequences, it is possible to create enzyme-oligonucleotide conjugates, which simplify and streamline the delivery of genetic material.
Enzyme-oligonucleotide conjugation also has a wide range of promising applications in drug delivery. By combining drugs with oligonucleotide sequences to form enzyme-oligonucleotide conjugation, it is possible to make the drugs enter the target cells specifically and reduce the toxic side effects of the drugs. In addition, enzyme-oligonucleotide conjugation can also improve the efficacy of drugs by altering the metabolic pathway and pharmacokinetics of the drugs.
| Service | Enzyme-Oligonucleotide Conjugation |
| Customer provides | Oligonucleotide sequence |
| Purification | QC analysis by MS, HPLC, or PAGE |
| Delivery | Typical delivery is lyophilized samples in individual vials that are fully labeled |
| Request a Quote | Inquiry |
Enzyme-oligonucleotide conjugation (EOC) involves linking enzymes with oligonucleotides (DNA or RNA) to create a conjugate that retains specific biological activity. This process can be achieved through covalent or non-covalent binding, enabling targeted delivery and precise regulation of biological functions.
EOC offers several advantages, including precise targeting of cells or tissues, enhanced stability, and the ability to modulate cellular processes. These conjugates can help in gene therapy, improve drug delivery, and regulate gene expression or inhibit unwanted biological activity.
The synthesis of EOCs involves selecting the appropriate enzymes (e.g., peroxidase, alkaline phosphatase) and oligonucleotides. The oligonucleotides are designed to contain reactive groups that can form covalent bonds with the enzyme, ensuring a stable conjugate. Non-covalent binding can also be used for certain applications.
EOCs improve drug delivery by targeting specific cells or tissues and enhancing drug uptake. The conjugation allows for controlled release, reducing the toxicity of drugs and optimizing their pharmacokinetics for better efficacy in the targeted tissue.
